Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Alltracel Pharmaceuticals Plc - Re Agreement

Abstract:
Alltracel Announces a NanopeuticsTM Product and Technology Development License Agreement with HemCon Medical Technologies to Serve the Military Market

Up front license fees and products expected to be on the market by 2008

Alltracel Pharmaceuticals Plc - Re Agreement

Dublin, Ireland and London, UK | Posted on July 19th, 2007

Alltracel Pharmaceuticals Plc., ("Alltracel", or "the Company"), (AIM:AP.L), the Healthcare Innovation Group focused on the Woundcare, Oral Care, Dermal Health and Cardiovascular Health markets, today announces its NanopeuticsTM subsidiary has signed a licensing agreement for its technology with HemCon Medical Technologies, Inc., the haemorrhage control market leaders in military markets.

Following the successful completion of product concept testing in the US and the Czech Republic in Q2 NanopeuticsTM has agreed a technology development agreement focused on Chitosan- based NanospiderTM technology for advanced woundcare applications in all relevant markets.

An undisclosed license payment is payable immediately and will develop into a royalty revenue model for the completed Chitosan-NanospiderTM products which are expected to reach the market by 2008.

Commenting on the announcement, Tony Richardson, Alltracel's Chief Executive Officer said;

"The NanopeuticsTM technology has been well received in the market place, and today's announcement that HemCon Medical have decided to license our technology underpins the full potential it offers. HemCon is the leading haemorrhage control company serving the military markets and we are excited that we will be working together with their team to bring the NanospiderTM technology to market by 2008."

####

About Alltracel Pharmaceuticals Plc.
Alltracel, (AIM: AP.L) ( http://www.alltracel.com ) the Healthcare Innovation Group is focused on taking proprietary technology from research right through to commercialisation in the global healthcare market.

Alltracel Pharmaceuticals Plc., ("Alltracel") was founded in 1996 and is a public company which listed on London's Alternative Investment Market in July 2001.

With corporate headquarters in Dublin, Ireland; Alltracel has a commercial office in London, England; R&D subsidiary in the Czech Republic and manufacturing facilities in Shenzhen, China. Alltracel also has a wide network of research, development and manufacturing partners in Europe, Asia and North America.

Alltracel operates via two main divisions Alltracel Healthcare Group and Alltracel Healthcare Technologies:

Alltracel Healthcare Group is focused on the commercialisation effort behind proven innovative technologies and services for the global healthcare market. Alltracel Healthcare Group has a range of stake holdings, joint ventures and wholly owned business units operating in a variety of healthcare categories including Wound Care, Oral Care, and Cardiovascular Health.

- Alltracel's specialist Oral Care subsidiary Westone ( http://www.westoneproducts.com ) is headquartered in London, England and is the leading contract supply and manufacturing partner for the European private label inter-dental market. Westone also partners with a number of leading oral care brands internationally.

- Alltracel's specialist Nanotechnology subsidiary Nanopeutics s.r.o. ( http://www.nanopeutics.net ) is headquartered in Liberec in the Czech Republic and is dedicated to the commercialisation of NanospiderTM technology for the global healthcare market.

Alltracel Healthcare Technologies specialises in innovation, research, development and the deployment of proprietary technology in the global healthcare market. Alltracel Healthcare Technologies has established a substantial intellectual property portfolio with patents in a number of healthcare applications areas such as Wound Care, Cardiovascular Health and Skin Care.

m-docTM & PhytopeuticsTM are trademarks of Alltracel Pharmaceuticals plc.

NanospiderTM and NanopeuticsTM are trademarks controlled by Nanopeutics s.r.o.

This information is provided by RNS
The company news service from the London Stock Exchange

For more information, please click here

Contacts:
Dublin: Karen Muldowney
Alltracel: +353 1 235 2162


London: Deborah Scott
Financial Dynamics: +44 207 831 3113

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

Arrowhead to Report Fiscal 2014 Third Quarter Financial Results- Conference Call Scheduled for Tuesday, August 12, 2014 - July 31st, 2014

New imaging agent provides better picture of the gut July 30th, 2014

Zenosense, Inc. July 29th, 2014

Optimum inertial design for self-propulsion: A new study investigates the effects of small but finite inertia on the propulsion of micro and nano-scale swimming machines July 29th, 2014

Announcements

Industrial Nanotech, Inc. to Publish PCAOB Audited Financials July 31st, 2014

Nanostructured metal-oxide catalyst efficiently converts CO2 to methanol: Highly reactive sites at interface of 2 nanoscale components could help overcome hurdle of using CO2 as a starting point in producing useful products July 31st, 2014

Carnegie Mellon Chemists Create Nanofibers Using Unprecedented New Method July 31st, 2014

Pressure probing potential photoelectronic manufacturing compound July 31st, 2014

Military

Pressure probing potential photoelectronic manufacturing compound July 31st, 2014

New imaging agent provides better picture of the gut July 30th, 2014

Watching Schrödinger's cat die (or come to life): Steering quantum evolution & using probes to conduct continuous error correction in quantum computers July 30th, 2014

Tough foam from tiny sheets: Rice University lab uses atom-thick materials to make ultralight foam July 29th, 2014

New-Contracts/Sales/Customers

East China University of Science and Technology Purchases Nanonex Advanced Nanoimprint Tool NX-B200 July 30th, 2014

University of Manchester selects Anasys AFM-IR for coatings and corrosion research July 30th, 2014

STFC takes delivery of the 100th Hitachi Tabletop SEM in the UK July 3rd, 2014

University of Maastricht Adds Complete Correlative Workflow from FEI to its Institute of Nanoscopy June 23rd, 2014

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE